Floatz logo

Vts-K

Analgesia

Theresa Jacob, PhD, MPHPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Analgesia cohort.

Asset / SponsorPhaseRating
NEPENTHE
Meri Mirceta
Phase 4BBB
LIDOCAINE
Meri Mirceta
Phase 4BB
DEXAMETHASONE
Meri Mirceta
Phase 4BB
ROPIVACAINE
Dr Kassiani Theodoraki
Phase 4BB
SUFENTANYL
Hospital Central do Funchal
Phase 4BB

View all 28 →

Same molecule, other indications

Vts-K is also rated in:

Central Nervous System DepressantsDormant
BB
Indicative ·
69 / 100
View asset →
Peripheral Nervous System AgentsDormant
BB
Indicative ·
69 / 100
View asset →
Anti-Inflammatory AgentsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →